In the NDD-CKD patient subgroup, the Hb level significantly rose after roxadustat treatment than that after placebo and darbepoetin alfa treatment (WMD: 1.36; 95% CI: 0.90–1.82; p < 0.00001; with heterogeneity [p < 0.00001]; Figure 3A and Table 3). This evidence concerns the gene GSTM1 and chronic kidney disease.